# Chemours Co: Form 10-Q for the period ended Sep 30, 2016

- Company: [Chemours Co](/companies/cc.md) (CIK 1627223)
- Form: 10-Q
- Filed: 2016-11-07
- Accepted by EDGAR: Nov 7, 2016, 16:35 ET
- Period: 2016-09-30
- Accession: 0001627223-16-000148
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1627223/000162722316000148/cc-2016930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1627223/000162722316000148/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-07-01 to 2016-09-30 | $1.40bn | us-gaap:Revenues |
| Revenue | 9 months, 2016-01-01 to 2016-09-30 | $4.08bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-07-01 to 2016-09-30 | $1.06bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2016-01-01 to 2016-09-30 | $3.27bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2016-07-01 to 2016-09-30 | $342.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2016-01-01 to 2016-09-30 | $811.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2016-07-01 to 2016-09-30 | $19.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2016-01-01 to 2016-09-30 | $60.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-07-01 to 2016-09-30 | $148.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2016-01-01 to 2016-09-30 | $454.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2016-07-01 to 2016-09-30 | $51.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2016-01-01 to 2016-09-30 | $157.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-07-01 to 2016-09-30 | $30.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2016-01-01 to 2016-09-30 | $25.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-07-01 to 2016-09-30 | $204.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-01-01 to 2016-09-30 | $237.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-07-01 to 2016-09-30 | $1.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2016-01-01 to 2016-09-30 | $1.30 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-07-01 to 2016-09-30 | $1.12 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2016-01-01 to 2016-09-30 | $1.31 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-07-01 to 2016-09-30 | 183,528,556 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2016-01-01 to 2016-09-30 | 182,541,932 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2016-01-01 to 2016-09-30 | $324.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2016-01-01 to 2016-09-30 | $235.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2016-01-01 to 2016-09-30 | $16.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2016-09-30 | $957.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-09-30 | $2.76bn | us-gaap:AssetsCurrent |
| Total assets | at 2016-09-30 | $6.29bn | us-gaap:Assets |
| Current liabilities | at 2016-09-30 | $1.44bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-09-30 | $5.91bn | us-gaap:Liabilities |
| Long-term debt | at 2016-09-30 | $3.71bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2016-09-30 | $32.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2016-09-30 | $377.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 60,659 characters.

### Introduction

Management’s discussion and analysis of our results of operations and financial condition, which we refer to as “MD&A,” supplements the unaudited interim consolidated financial statements included in this quarterly report and is intended to provide an understanding of our financial condition, changes in financial condition and results of operations. The discussion and analysis presented below refers to and should be read in conjunction with the unaudited interim consolidated financial statements included in this quarterly report, as well as our audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2015.

Unless the context otherwise requires, references herein to “The Chemours Company,” “Chemours,” “the company,” “our company,” “we,” “us,” and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to “DuPont” refers to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.

### Cautionary Statements About Forward-Looking Statements

This section and other parts of this quarterly report contain forward-looking statements, within the meaning of the federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words “believe,” “expect,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date the statements were made.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours’ control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. Factors that could cause or contribute to these differences include those discussed in the “Forward-Looking Statements” and the “Risk Factors” sections in our Annual Report on Form 10-K for the year ended December 31, 2015. The Company assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

### Overview

Chemours is a leading global provider of products that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide (“TiO2”), refrigerants, industrial fluoropolymer resins and a portfolio of industrial chemicals including sodium cyanide.

Chemours manages and reports operating results through three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Our position with each of these businesses reflects the strong value proposition we provide to our customers based on our long history and reputation in the chemical industry for safety, quality and reliability.

#### Chemours Five-Point Transformation Plan

Immediately after Chemours became an independent public company, we began to make changes to our organization, cost structure and portfolio of businesses in order to transform our company into a higher growth chemistry company. The objectives of our multi-year five-point transformation plan are to improve our financial performance, streamline and strengthen our portfolio and reduce our leverage by:

1\. Reducing our costs through a simpler business model;

2\. Optimizing our portfolio to focus on our businesses where we have leading positions;

3\. Growing our market positions where we have competitive advantages;

4\. Refocusing our investments by concentrating our capital expenditures on our core businesses; and

5\. Enhancing our organization to deliver our values and support our transformation to a higher-value chemistry company.

Through cost reduction and growth, Chemours expects the transformation plan to deliver $500 million of incremental Adjusted EBITDA improvement over 2015 through 2017. Based on our anticipated cost reduction and growth initiatives, we expect that our cost savings of approximately $350 million and approximately $150 million in improvements from growth initiatives will also improve our pre-tax earnings by similar amounts through 2017. Results of our transformation actions are discussed in the Recent Developments, Results of Operations, Segment Reviews and Outlook sections of this MD&A.

### Recent Developments

On June 13, 2016, the Company entered into an asset purchase agreement with Veolia North America (“Veolia”), pursuant to which Veolia agreed to acquire Chemours’ Sulfur Products business (“Sulfur business”) of its Chemical Solutions segment for a purchase price of $325 million in cash, subject to customary working capital and other adjustments, of which approximately $10 million was received in May 2016. The Company completed the sale on July 29, 2016 and received the remaining proceeds of approximately $311 million, net of estimated working capital adjustments. The sale is still subject to certain customary post-closing conditions.

On April 22, 2016, the Company entered into a Stock and Asset Purchase Agreement with LANXESS Corporation (“Lanxess”), pursuant to which Lanxess has agreed to acquire Chemours’ Clean & Disinfect product line (the “C&D business”) by acquiring certain Chemours' subsidiaries and assets comprising the C&D business for a purchase price of $230 million in cash, subject to customary working capital and other adjustments. The Company completed the sale on August 31, 2016 and received $223 million of cash, net of working capital adjustments and approximately $2 of cash transferred. The sale is still subject to certain customary post-closing conditions.

The Company expects to use the proceeds from the above sales to fund our future capital expenditures.

### Our Third Quarter 2016 Results and Business Highlights

Net sales for the three months ended September 30, 2016 were $1.4 billion, a decrease of 6% from $1.5 billion for the three months ended September 30, 2015. Net sales for the nine months ended September 30, 2016 were $4.1 billion, a decrease of 6% from $4.4 billion for the nine months ended September 30, 2015. These decreases were driven primarily by the portfolio changes from divestitures in the Chemical Solutions segment described below.

We recognized net income of $204 million and $237 million for the three and nine months ended September 30, 2016, respectively, compared with a net loss of $29 million and $4 million for the three and nine months ended September 30, 2015, respectively. Our results for the quarter reflect $172 million of gain on sale of the C&D business, improvements from cost reductions initiatives, improved TiO2 pricing, and strong Fluoroproducts performance, partially offset by asset impairment charges of $46 million and $104 million for the three and nine months ended September 30, 2016, respectively, in the Chemical Solutions segment.

Our Adjusted EBITDA was $268 million and $169 million for the three months ended September 30, 2016 and 2015, respectively, and $583 million and $441 million for the nine months ended September 30, 2016 and 2015, respectively. Our results for the 2016 periods reflect improvements in average prices in Titanium Technologies and improved profitability in Fluoroproducts, including growth in OpteonTM sales, partially offset by the impact of divestitures within the Chemical Solutions segment.

### Results of Operations

*(Dollars in millions)*

|  | Three months ended September 30, 2016 | 2015 | Nine months ended September 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,398 | $1,486 | $4,078 | $4,357 |
| Cost of goods sold | 1,056 | 1,222 | 3,267 | 3,615 |
| Gross profit | 342 | 264 | 811 | 742 |
| Selling, general and administrative expense | 148 | 157 | 454 | 481 |
| Research and development expense | 19 | 18 | 60 | 68 |
| Restructuring and asset related charges, net | 60 | 184 | 145 | 245 |
| Goodwill impairment | — | 25 | — | 25 |
| Total expenses | 227 | 384 | 659 | 819 |
| Equity in earnings of affiliates | 9 | 7 | 17 | 18 |
| Interest expense, net | (51) | (51) | (157) | (79) |
| Other income, net | 161 | 57 | 250 | 71 |
| **Income (loss) before income taxes** | 234 | (107) | 262 | (67) |
| Provision (benefit from) for income taxes | 30 | (78) | 25 | (63) |
| **Net income (loss)** | 204 | (29) | 237 | (4) |
| Less: Net income attributable to noncontrolling interests | — | — | — | — |
| **Net income (loss) attributable to Chemours** | $204 | $(29) | $237 | $(4) |

### Net Sales

Net sales for the three months ended September 30, 2016 were $1.4 billion, a decrease of approximately 6% compared to $1.5 billion in the same period in 2015. Net sales for the nine months ended September 30, 2016 were $4.1 billion, a decrease of approximately 6% compared to $4.4 billion in the same period in 2015.

The decreases in net sales in the three and nine months ended September 30, 2016 were driven by portfolio changes from divestitures and lower selling prices resulting from the impact of lower raw materials costs on contractual pass-through terms in the Chemical Solutions segment. In addition, decrease in net sales for the nine months ended September 30, 2016 were also impacted by lower selling prices for TiO2 in the Titanium Technologies segment year over year. In the Fluoroproducts segment, the growth in OpteonTM was offset by weaker demand and unfavorable product mix of fluoropolymer products.

The table below shows the impact of price, volume, currency and portfolio changes on net sales for the three and nine months ended September 30, 2016 compared with the three and nine months ended September 30, 2015:

| Change in net sales from prior period | Three Months Ended September 30, 2016 | Nine Months Ended September 30, 2016 |
| --- | ---: | ---: |
| Price | (1)% | (4)% |
| Volume | —% | 1% |
| Currency | —% | (1)% |
| Portfolio / Other | (5)% | (2)% |
| Total Change | (6)% | (6)% |

For detailed discussion of net sales, see the Segment Reviews section of this MD&A.

### Cost of goods sold

Cost of goods sold (COGS) decreased by 14% and 10% for the three and nine months ended September 30, 2016, respectively, when compared to the same periods in 2015. The decreases were primarily driven by lower operating costs, including lower raw materials and overhead costs, and improvement in plant utilization, which decreased COGS by approximately 9% and 7% for the three and nine months ended September 30, 2016, respectively. Portfolio changes primarily in our Chemical Solutions segment also decreased COGS by approximately 5% and 2% for the three and nine months ended September 30, 2016, respectively. These decreases were partially offset by inventory write-downs in the Chemical Solutions segment of $2 million and $7 million in the three and nine months ended September 30, 2016 as a result of the previously announced reactive metals solution restructuring, $5 million assets write-off related to the cyanides business of our Chemical Solutions segment in the nine months ended September 30, 2016 and a $6 million increase in performance related compensation accruals in the nine months ended September 30, 2016.

### Selling, general and administrative expense

Selling, general and administrative (SG&A) expense decreased by 6% to $148 million for the three months ended September 30, 2016 and decreased by 6% to $454 million for the nine months ended September 30, 2016, when compared to the same periods in 2015.

The decrease in SG&A for the three months ended September 30, 2016 was due to our cost reduction initiatives, including a global workforce reduction and other initiatives in connection with the transformation plan, that contributed to an approximate 12% reduction in SG&A. The decrease was partially offset by increase in performance related compensation accruals by approximately $5 million, and legal settlements and related costs of $2 million.

The decrease in SG&A in the nine months ended September 30, 2016 was primarily driven by lower pension costs and cost reduction initiatives, including the global workforce reduction and other initiatives in connection with the transformation plan, which contributed to an approximate 17% reduction in SG&A. These decreases were partially offset by increased performance related compensation accruals of approximately $25 million, transaction costs incurred primarily in connection with the sale of the C&D and Sulfur businesses of $18 million and legal settlements and related costs of $11 million.

### Research and development expense

Research and development (R&D) expense increased by $1 million and decreased by $8 million for the three and nine months ended September 30, 2016, respectively, when compared to the same period in 2015.

R&D spend was driven by decisions to refocus on fewer higher return projects. The global workforce reduction initiative also impacted the R&D function, which contributed to the decrease in R&D expense in the nine months ended September 30, 2016.

### Restructuring and asset-related charges, net

For the three and nine months ended September 30, 2016, we recorded pre-tax charges of approximately $60 million and $145 million, respectively, compared to $184 million and $245 million for the three and nine months ended September 30, 2015, respectively, for employee separation, decommissioning and other asset-related charges in connection with several restructuring actions initiated in the second half of 2015.

Charges in the three and nine months ended September 30, 2016 consist primarily of $5 million and $24 million, respectively, of decommissioning and dismantling activities related to the closure of Edge Moor manufacturing plant in Titanium Technology segment, $1 million and $6 million, respectively, of decommissioning activities related to certain production lines in Fluoroproducts segment, and $7 million and $6 million, respectively, of contract termination and decommissioning activities related to the reactive metals solution (“RMS”) manufacturing facility in Chemical Solutions segment. We also recorded in the Chemical Solutions segment $46 million of asset impairment charge in the three months ended September 30, 2016 related to the aniline facility in Pascagoula, Mississippi, and $58 million in the nine months ended September 30, 2016 of asset impairment charges in connection with the sale of the Sulfur business.

Charges for the three and nine months ended September 30, 2015 consist primarily of asset related charges of $114 million in the Titanium Technologies segment related to the write-off of substantially all of the Edge Moor plant assets’ carrying value, $8 million in the Fluoroproducts segment related to property, plant and equipment accelerated depreciation, and $45 million in the Chemical Solutions segment related to the RMS manufacturing facility asset impairment. We also recorded $17 million and $78 million of employee separation costs in the three and nine months ended September 30, 2015, respectively, related to the plant and product line closures for the Titanium Technologies and Fluoroproducts segments, and the 2015 restructuring program.

For details related to the “Restructuring and asset related charges, net”, see Note 5 to the interim consolidated financial statements.

### Interest expense, net

We incurred interest expense of $51 million and $157 million for the three and nine months ended September 30, 2016, respectively, compared to $51 million and $79 million for the three and nine months ended September 30, 2015, respectively.

Interest expense for the three months ended September 30, 2016 includes approximately $4 million of gain on debt extinguishment during the third quarter of 2016, offset by lower capitalized interest due to the completion of our Altamira plant expansion in April 2016.

Interest expense is higher in the nine months ended September 30, 2016 because the related long-term debt was outstanding for the full nine months in 2016 compared to 2015 when the long-term debt was issued in May 2015. In addition, we recorded approximately $4 million of non-cash write off of unamortized debt issuance costs attributable to the reduction in our revolver commitment during the first quarter of 2016. These increases were partially offset by approximately $10 million of gain on debt extinguishment in 2016 (see Note 15 to the interim consolidated financial statements).

### Other income, net

Other income, net increased by $104 million for the three months ended September 30, 2016 and increased by $179 million for the nine months ended September 30, 2016 when compared to the same periods in 2015.

For the three months ended September 30, 2016, other income primarily includes a $169 million gain on sale primarily in connection with the sale of our C&D business, partially offset by foreign currency exchange losses of $17 million driven by continued strengthening of the U.S. dollar primarily against the Mexican peso, compared to a foreign currency exchange gain of $44 million in 2015, which was mainly driven by a net gain from foreign currency forward contracts.

For the nine months ended September 30, 2016, other income primarily includes a $258 million gain on sale primarily in connection with the sale of our C&D business and the sale of our aniline facility in Beaumont, Texas, partially offset by foreign currency exchange losses of approximately $37 million driven by continued strengthening of the U.S. dollar primarily against the Mexican peso compared to a foreign currency exchange gain of $47 million in 2015, which was mainly driven by the net gain from foreign currency forward contracts.

For additional details of other income, net and foreign currency forward contracts, see Note 7 and Note 17 to the interim consolidated financial statements.

### Provision for (benefit from) income taxes

For the three months ended September 30, 2016 and 2015, Chemours recorded a provision for income tax of $30 million and a benefit from income tax of $78 million, respectively, or an effective income tax rate of approximately 13% and 73%, respectively. For the nine months ended September 30, 2016 and 2015, Chemours recorded a provision for income tax of $25 million and a benefit from income tax of $63 million, respectively, or an effective income tax rate of 9% and 94%, respectively.

The $108 million and $88 million increase in provision for income tax for the three and nine months ended September 30, 2016, respectively, and the corresponding changes in the effective income tax rates were primarily due to the Company’s geographical mix of earnings. The gain on the sale of assets and business (see Note 6) resulted in an increase in tax expense and a corresponding change in the effective income tax rate for the period ended September 30, 2016 as compared to the period ended September 30, 2015. These increases in tax provision were partially offset by restructuring charges, asset impairments and foreign currency exchange losses recognized in the period ended September 30, 2016.

### Segment Reviews

The following table represents Chemours’ total consolidated Adjusted EBITDA by segment:

*(Dollars in millions)*

|  | Three months ended September 30, 2016 | 2015 | Nine months ended September 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Titanium Technologies | 144 | 80 | 309 | 264 |
| Fluoroproducts | 143 | 91 | 333 | 220 |
| Chemical Solutions | 9 | 8 | 30 | 13 |
| Corporate and Other | (28) | (10) | (89) | (56) |
| Total | $268 | $169 | $583 | $441 |

Adjusted EBITDA represents our primary measure of segment performance and is defined as income (loss) before income taxes excluding the following:

- interest expense, depreciation and amortization,
- non-operating pension and other postretirement employee benefit costs, which represent the components of net periodic pension costs (income) excluding service cost component
- exchange losses (gains),
- employee separation, asset-related charges and other charges, net,
- asset impairments,
- losses (gains) on sale of business or assets, and
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

A tabular reconciliation of Adjusted EBITDA to net income (loss) for the three and nine months ended September 30, 2016 and 2015 is included in the Non-GAAP Financial Measures section of this Item 2.

### Titanium Technologies

*(Dollars in millions)*

|  | Three months ended September 30, 2016 | 2015 | Nine months ended September 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Segment Net Sales | $625 | $616 | $1,742 | $1,803 |
| Adjusted EBITDA | 144 | 80 | 309 | 264 |
| Adjusted EBITDA Margin | 23% | 13% | 18% | 15% |

| Change in segment net sales from prior period | Three months ended September 30, 2016 | Nine months ended September 30, 2016 |
| --- | ---: | ---: |
| Price | 1% | (6)% |
| Volume | —% | 3% |
| Currency | —% | —% |
| Portfolio / Other | —% | —% |
| Total Change | 1% | (3)% |

***Segment Net Sales:*** Net sales increased by 1% for the three months ended September 30, 2016 and decreased by 3% for the nine months ended September 30, 2016 when compared with the same periods in 2015.

The increase in sales in the three months ended September 30, 2016 was primarily due to improvement in global average selling prices during 2016. Our TiO2 sales volume also increased in the third quarter by approximately 2% due to the higher demand in all regions except China, offset by lower volumes in non-TiO2 products.

The decrease in net sales in the nine months ended September 30, 2016 was primarily due to lower average selling prices year over year, partially offset by an increase in sales volume due to higher demand in Europe and the United States. Our sales volume in 2016 was in line with seasonal and historical trends while 2015 experienced an unusually low volume particularly in the first quarter.

***Adjusted EBITDA and Adjusted EBITDA margin:*** Adjusted EBITDA and Adjusted EBITDA margin increased during the three and nine months September 30, 2016 when compared to the same periods in 2015.

The increase in Adjusted EBITDA of approximately 80% for the three months ended September 30, 2016 and the corresponding increase in Adjusted EBITDA margin was primarily driven by selling price increases and productivity improvement initiatives, which increased Adjusted EBITDA by approximately 14% and 68%, respectively. The productivity improvement initiatives resulted in lower raw materials and plant operating costs.

The increase in Adjusted EBITDA of approximately 17% for the nine months ended September 30, 2016 and the corresponding increase in Adjusted EBITDA margin was primarily driven by productivity improvement initiatives including the impact of the Edge Moor plant shut-down and global headcount reductions, which increased Adjusted EBITDA by approximately 56%. The productivity improvement initiatives resulted in lower raw materials and lower plant operating costs. The increase was partially offset by lower average selling price year-over-year, which decreased adjusted EBITDA by approximately 42%.

### Fluoroproducts

*(Dollars in millions)*

|  | Three months ended September 30, 2016 | 2015 | Nine months ended September 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Segment Net Sales | $591 | $575 | $1,695 | $1,715 |
| Adjusted EBITDA | 143 | 91 | 333 | 220 |
| Adjusted EBITDA Margin | 24% | 16% | 20% | 13% |

| Change in segment net sales from prior period | Three months ended September 30, 2016 | Nine months ended September 30, 2016 |
| --- | ---: | ---: |
| Price | (2)% | —% |
| Volume | 5% | 1% |
| Currency | —% | (2)% |
| Portfolio / Other | —% | —% |
| Total Change | 3% | (1)% |

***Segment Net Sales:*** Net sales increased by 3% for the three months ended September 30, 2016 and decreased by 1% for the nine months ended September 30, 2016 in comparison with the same period in 2015. Stronger demand for Opteon™ refrigerant in both Europe and the United States delivered a significant increase in volume over the prior period, partially offset by lower volume over the prior period due to the phase down of HCFCs refrigerants (i.e., Freon™) as stipulated by the Montreal Protocol, and by lower selling prices for fluoropolymer products due to competitive pricing pressure. For the nine months ended September 30, 2016, unfavorable foreign currency impact, primarily against the Euro and Brazilian real resulted in an overall decrease in net sales.

***Adjusted EBITDA and Adjusted EBITDA margin:*** Adjusted EBITDA and Adjusted EBITDA margin increased during the three and nine months ended September 30, 2016, respectively,when compared to the same periods in 2015.

Adjusted EBITDA increased by 57% and 51% during the three and nine months ended September 30, 2016, respectively, due primarily to margin improvements and cost reductions from cost savings initiatives. Margin improvement from fluorochemicals sales, including growth in Opteon™ but excluding currency impact, contributed an increase of approximately 40% and 32% in the three and nine months ended September 30, 2016, respectively, while cost reduction initiatives contributed an increase of approximately 20% and 29% for the three and nine months ended September 30, 2016, respectively. In addition, we incurred approximately $22 million or approximately 10% of incremental costs in the nine months ended September 30, 2015 due to plant outages in certain of our manufacturing facilities in the United States that did not recur in 2016. These improvements were partially offset by lower selling price and unfavorable product mix of fluoropolymers. Overall unfavorable currency in the nine months ended September 30, 2016 also resulted in a decrease in adjusted EBITDA by approximately 11%.

### Chemical Solutions

*(Dollars in millions)*

|  | Three months ended September 30, 2016 | 2015 | Nine months ended September 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Segment Net Sales | $182 | $295 | $641 | $839 |
| Adjusted EBITDA | 9 | 8 | 30 | 13 |
| Adjusted EBITDA Margin | 5% | 3% | 5% | 2% |

| Change in segment net sales from prior period | Three months ended September 30, 2016 | Nine months ended September 30, 2016 |
| --- | ---: | ---: |
| Price | (7)% | (8)% |
| Volume | (5)% | (4)% |
| Currency | —% | —% |
| Portfolio / Other | (26)% | (12)% |
| Total Change | (38)% | (24)% |

***Segment Net Sales:*** Net sales decreased by 38% and 24% in the three and nine months ended September 30, 2016 respectively, compared with the same periods in 2015. These decreases were primarily due to a portfolio change resulting from the sale of our aniline facility in Beaumont, Texas, our C&D business and our Sulfur business. In addition, sales decreased due to lower selling prices resulting from the impact of lower raw materials costs on contractual pass-through terms, and lower sales volume across all business units except Sulfur during the three and nine months ended September 30, 2016 due to soft demand.

***Adjusted EBITDA and Adjusted EBITDA margin:*** Adjusted EBITDA increased in the three months ended September 30, 2016 and increased in the nine months ended September 30, 2016 when compared to the same periods in 2015.

For the three months ended September 30, 2016, Adjusted EBITDA increased by $1 million reflecting lower operating costs partially offset by the impacts of the divestitures. For the nine months ended September 30, 2016, despite the decreases in net sales, Adjusted EBITDA and Adjusted EBITDA margin increased due primarily to the cost reduction efforts, including the global headcount reductions implemented in 2015, and improvement in plant operating costs.

### 2016 Outlook

With our transformation plan on track, we are achieving our anticipated cost reductions primarily from actions taken during 2015 including facilities closures, headcount reductions, procurement and productivity enhancements, suspension of 2016 annual salary increases globally, subject to contractual and legal limitations, and suspension of discretionary contribution component in our U.S. 401(k) plan; and additional cost reduction initiatives during 2016. Based on our anticipated cost reduction and growth initiatives, we continue to expect cost savings of approximately $350 million and approximately $150 million in improvements from growth initiatives that together will also improve our pre-tax earnings by similar amounts through 2017. To date, we have achieved approximately $160 million in cost savings and we continue to implement additional cost reduction initiatives to realize our target of reducing structural costs.

For the remainder of 2016, we believe that those cost reductions and our growth initiatives in our transformation plan along with TiO2 price increases will deliver full year Adjusted EBITDA between $740 million and $775 million based on a net income range of approximately $265 million to $290 million. We expect our full year capital expenditures in 2016 to approach $350 million primarily due to the shift in the timing of the cyanide expansion and more efficient spending. We continue to expect to generate positive free cash flow for the full year 2016. Our outlook reflects our current visibility and expectations on our strategic actions and market factors, such as currency movements, TiO2 pricing, and end-market demand.

A reconciliation of the full year estimated Adjusted EBITDA target to estimated net income is included in the Non-GAAP Financial Measures section of this Item 2.

### Liquidity & Capital Resources

Chemours’ primary source of liquidity is cash generated from operations, available cash and borrowings under the credit facilities as described below. We believe these sources are sufficient to fund our planned operations and to meet our interest, dividend and contractual obligations. Our financial policy seeks to deleverage by using free cash flow and proceeds from asset sales to repay outstanding borrowings, selectively invest for growth to enhance our portfolio including certain strategic capital investments, and return cash to shareholders through dividend payments.

Chemours’ operating cash flow generation is driven by, among other things, global economic conditions generally and the resulting impact on demand for our products, raw material and energy prices, and industry-specific issues, such as production capacity and utilization. Chemours has generated strong operating cash flow through various industry and economic cycles evidencing the operating strength of our businesses. Over the industry cycles in recent years, cash flows from operating activities increased in years leading up to the historical peak profitability achieved in 2011, and have decreased annually since that time. Despite the challenging market conditions in the TiO2 industry since the historical peak profitability in 2011, we anticipate that through our cost reduction efforts and growth initiatives, our operations will provide sufficient liquidity to implement the transformation plan and support cash needs for the business.

Over the next 12 months, we expect to make interest payments, capital expenditures, principal repayments, and restructuring payments. We may also use our available cash to reduce our indebtedness, to the extent permitted, and improve our leverage position. We expect to fund these payments through cash generated from operations, asset dispositions, available cash and borrowings under the revolving credit facility. We anticipate that our operations and revolving credit facility will provide sufficient liquidity over the next 12 months. The availability under our Revolving Credit Facility is subject to the last 12 months of our consolidated EBITDA as defined under the credit agreement.

As of September 30, 2016 and December 31, 2015, we had $577 million and $271 million, respectively, of cash and cash equivalents on our balance sheet held by our foreign subsidiaries, all of which is readily convertible into currencies used in our operations, including the U.S. dollar. Cash and earnings of our foreign subsidiaries are generally used to finance their operations and capital expenditures. At September 30, 2016 and December 31, 2015, management believed that sufficient liquidity was available in the United States, and it is our intention to indefinitely reinvest undistributed earnings of our foreign subsidiaries outside of the United States. No deferred tax liabilities have been recognized with regard to the approximately $577 million and $271 million of cash of our foreign subsidiaries as of September 30, 2016 and December 31, 2015, respectively, and undistributed earnings. The potential tax implications of the repatriation of unremitted earnings are driven by facts at the time of distribution, therefore, it is not practicable to estimate the income tax liabilities that might be incurred if such cash and earnings were repatriated to the United States.

### Cash Flows

The following table sets forth a summary of the net cash provided by (used for) operating, investing and financing activities.

*(Dollars in millions)*

|  | Nine months ended September 30, 2016 | 2015 |
| --- | ---: | ---: |
| Cash provided by (used for) operating activities | $324 | $(120) |
| Cash provided by (used for) investing activities | 469 | (355) |
| Cash (used for) provided by financing activities | (230) | 695 |

#### Operating Activities

Cash provided by operating activities improved by $444 million for the nine months ended September 30, 2016 when compared to the same periods in 2015 due primarily to working capital improvements and the advance payment of $190 million that we received from DuPont in February 2016 of which approximately $97 million has been utilized during the nine months ended September 30, 2016. Partially offsetting the increase was interest payments in 2016 of approximately $130 million versus approximately $22 million in 2015.

#### Investing Activities

Cash provided by investing activities for the nine months ended September 30, 2016 includes the $140 million proceeds from the sale of our aniline facility in Beaumont, Texas, $321 million net proceeds from the sale of the Sulfur business and $223 million net proceeds from the sale of the C&D business (see Note 6 to the interim consolidated financial statements for further details), as well as $22 million proceeds from a sale of land in Repauno, New Jersey. These cash inflows were offset by capital expenditures during the period of $235 million. Our capital expenditures decreased by approximately $157 million when compared to the same period in 2015 due to lower spending primarily from the completion of our Altamira plant expansion in April 2016 and no separation-related expenditures incurred during 2016.

We expect our full year capital expenditures in 2016 to approach $350 million primarily due to the shift in the timing of the cyanide expansion.

#### Financing Activities

Through the third quarter 2016, utilizing our available cash, we repurchased a portion of our senior secured term loans with an aggregate principal amount of $50 million for $49 million in cash, a portion of our 2023 Notes with an aggregate principal amount of $116 million for $107 million in cash, and a portion of our Euro Notes with an aggregate principal amount of $42 million for $39 million in cash. These senior loan repurchases were in addition to our quarterly required repayments on the senior secured term loans equivalent to 1% per annum of its original principal. We also declared and paid approximately $16 million of dividends to our shareholders, equivalent to $0.09 per share. Subsequent to September 30, 2016, we repurchased additional 2023 Notes with an aggregate principal amount of $76 million for $75 million in cash and additional Euro Notes with an aggregate principal amount of $31 million for $29 million in cash, completing approximately $315 million in total long-term debt repurchases to date.

Through June 2015, DuPont managed Chemours’ cash and financing arrangements and all excess cash generated through earnings were deemed remitted to DuPont and all sources of cash were deemed funded by DuPont. For the nine-month period ended September 30, 2015, Chemours had a net transfer to DuPont of approximately $2.9 billion. Also, during that period, Chemours remitted approximately $3.4 billion to DuPont in the form of a dividend, using cash received from issuance of debt and paid $100 million of dividends to shareholders. These cash outflows were partially offset by $247 million of cash provided by DuPont at June 30, 2015 pursuant to the separation agreement.

### Current Assets

*(Dollars in millions)*

|  | September 30, 2016 | December 31, 2015 |
| --- | ---: | ---: |
| Cash and cash equivalents | $957 | $366 |
| Accounts and notes receivable - trade, net | 881 | 859 |
| Inventories | 846 | 972 |
| Prepaid expenses and other | 73 | 104 |
| Total current assets | $2,757 | $2,301 |

Accounts and notes receivable - trade, net at September 30, 2016 increased by $22 million compared to December 31, 2015 primarily due to an increase sales in the third quarter of 2016 over fourth quarter of 2015 and favorable currency translation of approximately $11 million. These increases were offset by approximately $22 million of accounts receivable disposed in connection with the sale of C&D and Sulfur businesses.

Inventories at September 30, 2016 decreased $126 million compared to December 31, 2015. The decrease was due to the continued effort to reduce inventory on hand as well as due to the lower raw material and production costs. In addition, we recorded approximately $7 million of inventory write-down in the Chemical Solutions segment in the nine months ended September 30, 2016 as a result of the previously announced RMS restructuring, and approximately $17 million of inventory disposed in connection with the sale of our aniline facility in Beaumont, Texas and sale of C&D and Sulfur businesses, partially offset by approximately $6 million favorable currency translation.

Prepaid expenses and other current assets at September 30, 2016 decreased by $31 million compared to December 31, 2015 due to sale of our aniline facility in Beaumont, Texas in February 2016, which was previously classified as assets held-for-sale for approximately $46 million and included in this account as of December 31, 2015. This decrease was offset by the prepayment of our annual insurance premium during the third quarter of 2016.

### Current Liabilities

*(Dollars in millions)*

|  | September 30, 2016 | December 31, 2015 |
| --- | ---: | ---: |
| Accounts payable | $835 | $973 |
| Short-term borrowings and current maturities of long-term debt | 32 | 39 |
| Other accrued liabilities | 569 | 454 |
| Total current liabilities | $1,436 | $1,466 |

As of September 30, 2016, accounts payable decreased by $138 million compared to December 31, 2015 due to lower capital expenditures, lower inventories and timing of payments to vendors.

Other accrued liabilities increased due to the advance payment we received from DuPont in February 2016, which was recorded as a deferred liability and approximately $93 million of this prepayment remains outstanding as of September 30, 2016, and net accrued interest of approximately $38 million. These increases were partially offset by approximately $56 million of severance payments during the year.

### Credit Facilities and Notes

Our credit agreement (as amended) provides a total revolver commitment under the revolving credit facility of $750 million. The proceeds of loans made under the revolving credit facility can be used to finance capital expenditures, acquisitions, working capital needs and for other general corporate purposes. Availability under the Revolving Credit Facility is subject to certain covenant limitations. At September 30, 2016, the facility had a full borrowing capacity of $750 million, from which we had $141 million of letters of credit issued and outstanding under this facility.

In September 2015, in connection with the Company's transformation plan announced in August 2015, we undertook a first amendment to the credit agreement to allow pro forma inclusion of future benefits from cost savings initiatives in the calculation of financial covenants that rely on consolidated EBITDA beginning from the quarter ended September 30, 2015. Since the revolver availability in any quarter is determined by the cushion remaining in the financial maintenance covenants at the end of the previous quarter, this amendment increased our access to the revolving credit facility.

In February 2016, we proactively pursued a second amendment to the credit agreement in order to ensure that we would retain adequate liquidity and sufficient cushion in the event of an unexpected, further significant decline in TiO2 pricing. The second amendment also provided further flexibility by allowing us to include, on a pro forma basis, future benefits of cost savings initiatives in the calculation of financial covenants that rely on consolidated EBITDA for an additional year, and increased the amount of the applicable cost savings benefits that could be utilized in the covenant calculation. In addition, the second amendment replaced the total net leverage ratio with senior secured net leverage ratio and modified the minimum required levels of the interest expense coverage ratio. These changes were designed to allow us to have full access to the revolving credit facility, provide flexibility to execute our transformation plan through 2017 and provide additional cushion in the event of an unexpected, further significant decline in TiO2 pricing. Furthermore, the amendment reduced the size of the revolving credit facility by $250 million to $750 million. With the on-going efforts to improve working capital usage as a part of our transformation plan, we believe that $750 million of revolver access will be sufficient to meet our working capital and other cash needs over the next 12 months.

The credit agreement, as amended, contains financial covenants which, solely with respect to the revolving credit facility, require us not to exceed a maximum senior secured net leverage ratio of 3.50 to 1.00 each quarter through December 31, 2016, 3.00 to 1.00 through June 30, 2017 and further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. We are also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict us and our subsidiaries’ ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. The senior secured credit facilities and the senior unsecured notes contain events of default customary for these types of financings, including cross default and cross acceleration provisions to material indebtedness of Chemours. We were in compliance with our debt covenants as of September 30, 2016.

In the event of default under the revolving credit facility, our lenders under the revolving credit facility can terminate their commitments thereunder, cease making further revolving loans and accelerate outstanding revolving loans. This would allow the lenders under the revolving credit facility to declare the outstanding term loans to be immediately due and payable and to institute foreclosure proceedings against the collateral securing the credit facility, which could force us into bankruptcy or liquidation. Any event of default or declaration of acceleration under the credit agreement also may result in an event of default under the indenture governing the notes. Any such default, event of default or declaration of acceleration could materially and adversely affect our results of operations and financial condition. Please see the section titled “Risks Related to our Indebtedness” of the “Risk Factors” section of our Annual Report Form 10-K for the year ended December 31, 2015 for additional detail.

There are no debt maturities prior to the year 2022, except, in accordance with the credit agreement, we are required to make principal payments related to the Term Loans of $4 million for the remainder of 2016 and $15 million in each year from 2017 to 2021. Debt maturities related to the Term Loans and the Notes in 2022 and beyond will be $3,698 million. In addition, following the end of each fiscal year commencing on the year ended December 31, 2016, we are also required to make additional principal repayments, depending on our leverage level as defined in the credit agreement, equivalent to up to 50% of excess cash flow based on certain leverage targets with stepdowns to 25% and 0% as actual leverage decreases to below 3.00 to 1.00 leverage target. See Note 15 to the interim consolidated financial statements included in this quarterly report on Form 10-Q for additional information related to our indebtedness.

### Supplier Financing

In 2015, we entered into a global paying services agreement with a financial institution. Under this agreement, the financial institution acts as the paying agent for Chemours with respect to accounts payable due to our suppliers who elect to participate in the program. The agreement allows our suppliers to sell their receivables to the financial institution at the discretion of both parties on terms that are negotiated between them. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers’ decisions to sell their receivables under this program. At September 30, 2016, the payment instructions from Chemours were $113 million. Pursuant to their agreement with the financial institution, certain suppliers may elect to get paid early at their discretion. The available capacity under this program can vary based on the number of investors participating in this program at any point in time.

### Contractual Obligations

Chemours’ contractual obligations at September 30, 2016 did not significantly change from its contractual obligations previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015, except that in January 2016, Chemours and DuPont entered into an agreement which set forth an advance payment of approximately $190 million for certain specified goods and services to be provided to DuPont over twelve to fifteen months under existing agreements with Chemours. Approximately $93 million of this prepayment remains outstanding as of September 30, 2016. See Note 4 to the interim consolidated financial statements included in this quarterly report on Form 10-Q for additional information.

### Off Balance Sheet Arrangements

Information with respect to Chemours’ guarantees is included in Note 16 to the interim consolidated financial statements of this Quarterly Report on Form 10-Q and in Note 19 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2015. Historically, Chemours has not made significant payments to satisfy guarantee obligations; however, Chemours believes it has the financial resources to satisfy these guarantees in the event required.

### Critical Accounting Policies and Estimates

Chemours’ significant accounting policies are described in “Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates” section and Note 3 to the consolidated financial statements in our Annual Report on Form 10-K. There have been no material changes to our critical accounting policies and estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015.

### Recent Accounting Pronouncements

See Note 3 to the interim consolidated financial statements included in this quarterly report on Form 10-Q for discussions of recent accounting pronouncements.

### Environmental Matters

#### Environmental Expenses

Environmental expenses charged to current operations include environmental operating costs and the increase in the remediation accrual, if any, during the period reported. As a result of its operations, Chemours incurs costs for pollution abatement activities including waste collection and disposal, installation and maintenance of air pollution controls and wastewater treatment, emissions testing and monitoring and obtaining permits. Chemours also incurs costs for environmental-related research and development activities including environmental field and treatment studies as well as toxicity and degradation testing to evaluate the environmental impact of products and raw materials. Management expects that such expenses in 2016 will be comparable to 2015 and, therefore, does not believe that year over year changes, if any, in environmental expenses charged to current operations will have a material impact on Chemours’ financial position, liquidity or results of operations.

#### Remediation Accrual

Annual expenditures in the near future are not expected to vary significantly from the range of such expenditures incurred during the past few years. Longer term, expenditures are subject to considerable uncertainty and may fluctuate significantly. There have been no significant changes to the remediation accrual at September 30, 2016 from December 31, 2015.

As of December 31, 2015, Chemours, through DuPont, has been notified of potential liability under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund) or similar state laws at about 174 sites around the United States, including approximately 22 sites for which Chemours does not believe it has liability based on current information. Active remediation is under way at approximately 53 of these sites. Approximately 66 sites have been resolved either by completing remedial actions with other Potentially Responsible Parties (PRPs) or participating in “de minimis buyouts” with other PRPs whose waste, like Chemours’, represented only a small fraction of the total waste present at a site. No new notices of potential liability at any sites were received during the three and nine months ended September 30, 2016.

At September 30, 2016, our consolidated balance sheet reflects an environmental liability of approximately $281 million relating to the above mentioned sites, as well as certain sites owned and/or operated by Chemours which, in management’s opinion, is appropriate based on existing facts and circumstances. The average time-frame over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15 to 20 years. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of other PRPs. In addition, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular there may be considerable variability between the remediation activities that are currently being undertaken or planned, as reflected in the liability recorded at September 30, 2016, and the ultimate actions that could be required.

Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may range up to approximately $600 million above the amount accrued at September 30, 2016. Based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the financial position, liquidity or results of operations of Chemours.

#### Pompton Lakes

See discussion under "Pompton Lakes" in Note 16 to the interim consolidated financial statements included in this quarterly report on Form 10-Q.

### PFOA

See discussion under “PFOA” in Note 16 to the interim consolidated financial statements included in this quarterly report on Form 10-Q.

### Non-GAAP Financial Measures

We prepare our financial statements in accordance with U.S. GAAP. To supplement our financial information presented in accordance with U.S. GAAP, we provide non-GAAP financial measures (“Adjusted EBITDA”, “Adjusted Net Income” and “Free Cash Flow”) to provide investors with a better understanding of the Company’s performance when analyzing changes in our underlying business between reporting periods and to allow for greater transparency with respect to supplemental information used by management in its financial and operational decision making. We utilize Adjusted EBITDA as the primary measure of segment profitability used by our Chief Operating Decision Maker (CODM).

Adjusted EBITDA is defined as income (loss) before taxes excluding the following:

- interest expense, depreciation and amortization,
- non-operating pension and other postretirement employee benefit costs, which represent the components of net periodic pension costs (income) excluding service cost component
- exchange losses (gains),
- employee separation, asset-related charges and other charges, net,
- asset impairments,
- losses (gains) on sale of business or assets, and
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

Adjusted Net Income (Loss) is defined as net income (loss) attributable to Chemours adjusted for items excluded from Adjusted EBITDA except interest expense, depreciation and amortization, and certain provision for (benefit from) income taxes. Free Cash Flow is defined as cash provided by (used in) operating activities less cash used for purchases of property, plant and equipment as disclosed in the consolidated statements of cash flows (a GAAP financial measure).

We believe the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company’s operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income and Free Cash Flow should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items. The non-GAAP financial measures we use may be defined differently from measures with the same or similar names used by other companies. This analysis, as well as the other information provided in this quarterly report on Form 10-Q, should be read in conjunction with the Company’s interim financial statements and notes thereto included in this quarterly report as well as the Company's consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.

The following table reconciles Adjusted EBITDA and Adjusted Net Income discussed above to net income attributable to Chemours for the periods presented:

*(Dollars in millions)*

|  | Three months ended September 30, 2016 | 2015 | Nine months ended September 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| **Net income (loss) attributable to Chemours** | $204 | $(29) | $237 | $(4) |
| Non-operating pension and other postretirement employee benefit (income) costs | (5) | (10) | (19) | 5 |
| Exchange losses (gains) | 17 | (44) | 37 | (47) |
| Restructuring charges | 14 | 139 | 41 | 200 |
| Asset related charges 1 | 46 | 70 | 109 | 70 |
| Gain on sale of assets or business | (169) | — | (258) | — |
| Transaction costs 2 | 2 | — | 18 | — |
| Legal and other charges 3 | 5 | — | 24 | — |
| (Benefit from) provision for income taxes relating to reconciling items 4 | (2) | (53) | (16) | (82) |
| **Adjusted Net Income** | 112 | 73 | 173 | 142 |
| Net income attributable to noncontrolling interests | — | — | — | — |
| Interest expense, net | 51 | 51 | 157 | 79 |
| Depreciation and amortization | 73 | 70 | 212 | 201 |
| All remaining provision for income taxes 4 | 32 | (25) | 41 | 19 |
| **Adjusted EBITDA** | $268 | $169 | $583 | $441 |

1 The three and nine months ended September 30, 2016 includes $46 million pre-tax asset impairment of our Pascagoula Aniline facility (see Note 12) and other asset write-offs. The nine months ended September 30, 2016 also included $58 million pre-tax asset impairment in connection with the sale of the Sulfur business (see Note 6) and other asset write-offs, which were recorded in the second quarter of 2016. The three and nine months ended September 30, 2015 includes $25 million of goodwill impairment (see Note 13) and $45 asset impairment of RMS facility (see Note 12). All of these charges are recorded in the Chemical Solutions segment.

2 Includes accounting, legal and bankers transaction fees incurred related to the Company's strategic initiatives, which includes pre-sale transaction costs incurred in connection with the sales of the C&D and Sulfur businesses (see Note 6).

3 Includes litigation settlements, water treatment accruals related to PFOA, and lease termination charges.

4 Total of provision for (benefit from) income taxes reconciles to the amount reported in the Interim Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015.

As discussed in the Outlook, we expect to deliver full year Adjusted EBITDA between $740 million and $775 million. The following table reconciles our Adjusted EBITDA targets to pre-tax income:

*(Dollars in millions)*

|  | 2016 Full Year Estimate Low | High |
| --- | ---: | ---: |
| **Net income attributable to Chemours** | $265 | $290 |
| Non-operating pension and other postretirement employee benefit (income) costs | (25) | (20) |
| Exchange losses 5 | 37 | 37 |
| Restructuring charges | 50 | 45 |
| Asset related charges 1 6 | 109 | 109 |
| Gain on sale of assets or business 6 | (258) | (258) |
| Transaction costs, legal and other charges 6 | 42 | 42 |
| Provision for income taxes relating to reconciling items 7 | (20) | (20) |
| **Adjusted net income** | 200 | 225 |
| Net income attributable to noncontrolling interests | — | — |
| Interest expense, net | 210 | 210 |
| Depreciation and amortization | 280 | 280 |
| All remaining provision for income taxes 7 | 50 | 60 |
| **Adjusted EBITDA** | $740 | $775 |

5 The amount represents the year-to-date net exchange losses incurred in the nine months ended September 30, 2016. Full year actual results could differ from the current estimate, and therefore could also change our estimated income before income taxes. Forecasting the remeasurement impact of foreign currency exchange fluctuation is not practical without unreasonable effort.

6 We do not expect to incur additional impairment, gain on sale of assets, transaction costs and legal and other charges. Therefore, the amounts included are the same as the actual amounts reported in the nine months period ended September 30, 2016.

7 Provision for (benefit from) income taxes were estimated based upon current geographical mix of earnings. Actual provision for (benefit from) income tax could defer from current estimate.

## Market risk

As filed, 3,124 characters.

We are exposed to changes in foreign currency exchange rates because of our global operations. As a result, we have assets, liabilities and cash flows denominated in a variety of foreign currencies. We are also exposed to changes in the prices of certain commodities that we use in production. Changes in these rates and commodity prices may have an impact on future cash flow and earnings. We manage these risks through normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We do not enter into derivative financial instruments for trading or speculative purposes.

Chemours enters into foreign currency forward contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring monetary assets and liabilities that Chemours holds which are denominated in non-functional currencies. These derivatives are stand-alone and have not been designated as a hedge. During the three and nine months ended September 30, 2016, we entered into various foreign currency forward contracts for currencies such as the Euro, Chinese yuan and Swiss francs among others, and had 61 open contracts with an aggregate notional U.S. dollar equivalent of $444 million, the fair value of which amounted to approximately $1 million of net unrealized loss.

In a hypothetical adverse change in the market prices or rates that existed at September 30, 2016, a 10% increase in the U.S. dollar against our outstanding hedged contracts on foreign currencies, such as the Euro and Chinese yuan, at the currency exchange rates as of September 30, 2016 would decrease our net loss by approximately $4 million, while a 10% depreciation of the U.S. Dollar against the same hedged currencies would increase our net loss by approximately $6 million.

Chemours hedges its net investment in certain European operations. Changes in the fair value of the hedge in the net investment of certain European operations are recorded in accumulated other comprehensive income (loss). For the three and nine months ended September 30, 2016, Chemours did not record any ineffectiveness and recognized a loss of $6 million and $9 million, respectively, on its net investment hedges within accumulated other comprehensive income (loss).

Chemours’ risk management programs and the underlying exposure are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by change in the value of the underlying exposure. See Note 17 to the interim consolidated financial statements for further information.

### Additional Information

See Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2015 for additional information on the Company’s utilization of financial instruments and an analysis of the sensitivity of these instruments. There have been no material changes in the market risks previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

## Controls and procedures

As filed, 1,450 characters.

### Evaluation of Disclosure Controls and Procedures

The Company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the Company’s reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of September 30, 2016, the Company’s Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective at the reasonable assurance level described above.

### Changes in Internal Control over Financial Reporting

There has been no change in the Company's internal control over financial reporting that occurred during the quarter ended September 30, 2016 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 137 characters.

There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015.

Filed Nov 7, 2016.
Source: SEC EDGAR, the filing index for accession 0001627223-16-000148. Last ingested by Listed: Nov 5, 2026, 19:57 ET. No prices; not investment advice.
